Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

Antibodies to citrullinated proteins (anti-cyclic-citrullinated peptide [anti-CCP] antibodies) are highly specific for rheumatoid arthritis (RA) and precede the onset of disease symptoms, indicating a pathogenetic role for these antibodies in RA. We recently showed that distinct genetic risk factors...

Full description

Bibliographic Details
Main Authors: van der Helm-van Mil, Annette HM, Verpoort, Kirsten N, Breedveld, Ferdinand C, Toes, René EM, Huizinga, Tom WJ
Format: Online
Language:English
Published: BioMed Central 2005
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1257421/
id pubmed-1257421
recordtype oai_dc
spelling pubmed-12574212005-10-19 Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis van der Helm-van Mil, Annette HM Verpoort, Kirsten N Breedveld, Ferdinand C Toes, René EM Huizinga, Tom WJ Research Article Antibodies to citrullinated proteins (anti-cyclic-citrullinated peptide [anti-CCP] antibodies) are highly specific for rheumatoid arthritis (RA) and precede the onset of disease symptoms, indicating a pathogenetic role for these antibodies in RA. We recently showed that distinct genetic risk factors are associated with either anti-CCP-positive disease or anti-CCP-negative disease. These data are important as they indicate that distinct pathogenic mechanisms are underlying anti-CCP-positive disease or anti-CCP-negative disease. Likewise, these observations raise the question of whether anti-CCP-positive RA and anti-CCP-negative RA are clinically different disease entities. We therefore investigated whether RA patients with anti-CCP antibodies have a different clinical presentation and disease course compared with patients without these autoantibodies. In a cohort of 454 incident patients with RA, 228 patients were anti-CCP-positive and 226 patients were anti-CCP-negative. The early symptoms, tender and swollen joint count, and C-reactive protein level at inclusion, as well as the swollen joint count and radiological destruction during 4 years of follow-up, were compared for the two groups. There were no differences in morning stiffness, type, location and distribution of early symptoms, patients' rated disease activity and C-reactive protein at inclusion between RA patients with and without anti-CCP antibodies. The mean tender and swollen joint count for the different joints at inclusion was similar. At follow-up, patients with anti-CCP antibodies had more swollen joints and more severe radiological destruction. Nevertheless, the distribution of affected joints, for swelling, bone erosions and joint space narrowing, was similar. In conclusion, the phenotype of RA patients with or without anti-CCP antibodies is similar with respect to clinical presentation but differs with respect to disease course. BioMed Central 2005 2005-06-14 /pmc/articles/PMC1257421/ /pubmed/16207336 http://dx.doi.org/10.1186/ar1767 Text en Copyright © 2005 van der Helm-van Mil et al, licensee BioMed Central Ltd.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author van der Helm-van Mil, Annette HM
Verpoort, Kirsten N
Breedveld, Ferdinand C
Toes, René EM
Huizinga, Tom WJ
spellingShingle van der Helm-van Mil, Annette HM
Verpoort, Kirsten N
Breedveld, Ferdinand C
Toes, René EM
Huizinga, Tom WJ
Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
author_facet van der Helm-van Mil, Annette HM
Verpoort, Kirsten N
Breedveld, Ferdinand C
Toes, René EM
Huizinga, Tom WJ
author_sort van der Helm-van Mil, Annette HM
title Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
title_short Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
title_full Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
title_fullStr Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
title_full_unstemmed Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
title_sort antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis
description Antibodies to citrullinated proteins (anti-cyclic-citrullinated peptide [anti-CCP] antibodies) are highly specific for rheumatoid arthritis (RA) and precede the onset of disease symptoms, indicating a pathogenetic role for these antibodies in RA. We recently showed that distinct genetic risk factors are associated with either anti-CCP-positive disease or anti-CCP-negative disease. These data are important as they indicate that distinct pathogenic mechanisms are underlying anti-CCP-positive disease or anti-CCP-negative disease. Likewise, these observations raise the question of whether anti-CCP-positive RA and anti-CCP-negative RA are clinically different disease entities. We therefore investigated whether RA patients with anti-CCP antibodies have a different clinical presentation and disease course compared with patients without these autoantibodies. In a cohort of 454 incident patients with RA, 228 patients were anti-CCP-positive and 226 patients were anti-CCP-negative. The early symptoms, tender and swollen joint count, and C-reactive protein level at inclusion, as well as the swollen joint count and radiological destruction during 4 years of follow-up, were compared for the two groups. There were no differences in morning stiffness, type, location and distribution of early symptoms, patients' rated disease activity and C-reactive protein at inclusion between RA patients with and without anti-CCP antibodies. The mean tender and swollen joint count for the different joints at inclusion was similar. At follow-up, patients with anti-CCP antibodies had more swollen joints and more severe radiological destruction. Nevertheless, the distribution of affected joints, for swelling, bone erosions and joint space narrowing, was similar. In conclusion, the phenotype of RA patients with or without anti-CCP antibodies is similar with respect to clinical presentation but differs with respect to disease course.
publisher BioMed Central
publishDate 2005
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1257421/
_version_ 1611378600797274112

Similar Items